



**ASX Announcement**

**March 6th 2024**

## **Atomo secures significant order for HIV Self-Tests for LMIC Territories**

SYDNEY, Australia March 6<sup>th</sup>, 2024 - Atomo Diagnostics Limited (ASX:AT1) (Atomo) is pleased to announce securing purchase orders from Viatris Healthcare Pty Ltd (Viatris) for approximately AUD \$970,000 worth of HIV Self-Tests, manufactured by Atomo under the Mylan brand for supply to a number of Low- and Middle-Income Countries (LMICs). The orders are for manufacture during H2 of FY24. Atomo considers the revenue from these orders to be material.

Mr Kelly said, “We have seen growing demand during FY24 for the Atomo HIV Self-Test here in Australia as well as across branded versions supplied to international markets. Following significant increases in sales to Europe and in Australia, it is good to now see emergent demand across LMIC markets from our global health partner for HIV testing, Viatris.”

*This announcement was authorised by the Managing Director & CEO.*

For more information, please contact:

John Kelly  
Atomo Diagnostics  
[john.kelly@atomodiagnostics.com](mailto:john.kelly@atomodiagnostics.com)  
Phone: +61 401 922 279

### **About Atomo**

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo’s unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health.

See more at [www.atomodiagnostics.com](http://www.atomodiagnostics.com)